阿托伐他汀对冠心病患者血清ghrelin水平的影响

目的：检测冠心病患者血清ghrelin的水平，探讨其与疾病严重程度的关系，并进一步观察阿托伐他汀治疗对其水平有无影响。方法：纳入64例冠心病患者和56名正常对照者，检测两组血清ghrelin水平有无差异。采用Gensini积分标准对冠心痛的病变程度进行定量评定，并分析其与血清ghrelin有无联系。64例冠心病患者再进一步随机分为常规治疗组和阿托伐他汀组，后者在常规治疗的基础上，另外服用阿托伐他汀10mg／d，治疗4周，观察治疗前后两组患者血清ghrelin水平的变化。结果：与正常组相比，冠心病患者的血清ghrelin水平明显降低，差异有统计学意义。Logistie回归分析表明，血清ghrelin降低是冠心病的独立危险因子。Spearman相关分析显示，血清ghrelin水平与Gensini积分呈显著负相关。治疗4周后，阿托伐他汀组的血清ghrelin水平较治疗前明显升高（P〈0．05）；而常规治疗组其血清水平无明显变化（P〉0．05）。结论：冠心病患者的血清ghrelin水平明显降低，并与疾病严重程度相关，阿托伐他汀具有升高冠心病患者血清ghrelin的作用。

Effects of atorvastatin on serum ghrelin levels in patients with coronary artery disease

Objective： To determine the serum levels of ghrelin in patients with coronary artery disease, and to examine the association of serum ghrelin with the severity of this disease, and further to explore the effect of atorvastatin on the serum levels of ghrelin in these patients. Methods：Serum levels of ghrelin were compared between 64 patients with coronary artery disease and 56 healthy controls. Gensini score was used to evaluate the severity of coronary artery disease. And the correlation of Gensini score with serum ghrelin levels was analyzed. Then the above patients were randomly divided into control group and atorvastatin group （32 patients in each group）. Patients in both groups were given regular treatment. In addition, patients in atorvastatin group were treated with atorvastatin （10 mg/d） for 4 weeks. Serum levels of ghrelin in the two groups were examined before and after treatment. Results： Serum levels of ghrelin were significantly decreased in patients with coronary artery disease compared with those in controls. Logistic regression analysis revealed that reduced level of serum ghrelin was an independent risk factor of coronary artery disease. Spearman analysis showed that serum levels of ghrelin were negatively correlated with Gensini score. After 4 weeks of treatment with atorvastatin, serum levels of ghrelin were significantly increased. However, no significant differences of serum ghrelin were found in control group before and after regular treatment. Conclusion： Serum level of ghrelin is significantly decreased in patients with coronary artery disease and correlates with the severity of this disease. Atorvastatin may increase the levels of ghrelin in serum for patients with coronary artery disease.